Description
Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete’s foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections.
This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been a factor. These are part of the factors that have lead to nearly 6-billion dollar antifungal drug industry.
Anti-Infectives, Second Edition, Volume I: Antifungals is a comprehensive review of the market for anti fungal drugs. This is the first volume of Kalorama Information’s 2nd edition of its popular three-part series on anti-infective markets. The report focuses on two segments of antifungal treatment: systemic and topical. The report covers both currently marketed and late stage development antifungal products in detail.
For both the systemic and topical antifungal markets, this report includes:
- U.S. and World Revenues
- Forecasts to 2011.
- Overview and Incidence Data
- Description of Products on the Market
- Review of Products in Development
- Competitive Analysis of Leading Providers.
- 10 Key Issues and Trends facing the antifungal industry
Revenues for each segment were generated using dollar and unit sales for each product. All market data pertain to the world market at the manufacturers’ level. Revenues and market share of major brands such as Lamisil, Diflucan, Sporanox, Cancidas, Vfend, and others are included.
Competitive analysis is provided for the year 2006. The forecasted market analysis for 2004-2011 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.
As part of Kalorama’s trusted information-gathering process, the information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information and developing forecasts.
For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
Table of Contents
CHAPTER ONE: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: Introduction
- Overview
- Introduction to Pathogens
- Antimicrobial Spectrum
- Bacterial Resistance
- Principles of Anti-infective Therapy
- Infecting Organism
- Antibiotic Sensitivity Testing
- Site of Infection
- Host Defenses and Organ Function
- Antibiotic Pharmcokinetics
- Monitoring Therapy
- Combination Therapy and Prophylactic Use
- Fungal Infections
- Types of Fungal Infections
- Superficial
- Systemic
- Histoplasmosis
- Coccidioidomycosis
- Blastomycosis
- Demographics and Statistics
CHAPTER THREE: Systemic Antifungal Drugs
- Overview
- Description of Products
- Allylamines
- Terbinafine (Lamisil – Novartis)
- Azoles
- Fluconazole (Diflucan – Pfizer)
- Ketoconazole (Nizoral, Johnson & Johnson)
- Miconazole (Monistat, Johnson & Johnson)
- Itraconazole (Sporanox, Johnson & Johnson)
- Posaconazole (Noxafil, Schering-Plough)
- Virconazole (Vfend, Pfizer)
- Polyene Macrolides
- Amphotericin B (Ambisome, Astellas; Abelcet, Enzon; Fungizone, Apothecon).
- Griseofluvin (Fulvicin, Schering)
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Flucytosine (Ancoban, Valeant)
- Echinocandins
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FOUR: Topical Antifungal Drugs
- Overview
- Description of Products
- Allylamines
- Naftifine (Naftin, Allergan)
- Terbinafine (Lamisil – Novartis)
- Butenafine (Mentax, Bertek)
- Azoles
- Miconazole (Monistat -Derm, OrthoDermatological)
- Clotrimazole (Mycelex, Bayer; Lotrimin, Schering)
- Ketoconazole (Nizoral, J&J; Xolegel, Barrier Therapeutics)
- Oxiconazole (Oxistat, GlaxoSmithKline/Elan)
- Econazole (Spectazole, Ortho Dermatological)
- Sulconazole (Exelderm, Westwood-Squibb)
- Terconazole (Terazol, Ortho Dermatological)
- Polyene Macrolides
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Ciclopirox (Penlac, Sanofi-Aventis/Dermik)
- Selenium sulfide (Selsun, Chattem Inc)
- Amorolfine (Loceryl, Roche)
- Alcortin (Iodoquinol, hydrocortisone, Primus Pharmaceuticals)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FIVE: Issues and Trends Affecting the Antifungal Market
- Introduction
- Fungal Infections and Immunocompromised Patients
- Reimbursement
- Infection Imaging
- Expanded Use of Azoles
- Drug Resistance and Interactions
- Standardized Susceptibility Testing
- Generic Impact and Availability
- Importance of Drug Delivery
- Rx-to-OTC Switches
- The Antifungal Market and Enchiocandins
chapter six: Antifungal Drugs: Total Market Size and Forecast
- Overview
- Total market Size and Forecast
CHAPTER SEVEN: Corporate Profiles
- Introduction
- Astellas Pharma Inc
- Barrier Therapeutics, Inc
- Johnson & Johnson Group
- Merck & Company, Inc
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc
- Schering-Plough Corporation
CHAPTER EIGHT: Company Directory
table of exhibits
Chapter One: Executive Summary
- Table 1-1: The World Market for Antifungal Drugs 2004-2011
- Figure 1-1: The World Market for Antifungal Drugs 2004-2011
Chapter Two: Introduction
- Table 2-1: Estimated World and U.S. Incidence of Fungal Infections (thousands)
- Figure 2-1: Estimated World and U.S. Incidence of Leading Fungal Infections
- Table 2-2: World Population by Selected Geographical Region, 2006-2050
- Figure 2-2: World Population by Selected Geographical Region, 2006-2050
- Table 2-3: Estimated World Population by Age and Geographical Region, 2006
- Figure 2-3: Estimated World Population by Age and Geographical Region, 2006
- Table 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
- Figure 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
Chapter Three: Systemic Antifungal Drugs
- Table 3-1: Allylamines
- Table 3-2: Azoles
- Table 3-3: Polyene Macrolides
- Table 3-4: Miscellaneous Antifungals
- Table 3-5: New Generic Drug Approvals for Systemic Antifungals, United States, 2004-2006
- Table 3-6: Systemic Antifungal Drugs in Development
- Table 3-7: The Market for Systemic Antifungal Drugs 2004-2011
- Figure 3-1: Systemic Antifungal Drug Market 2004-2011
- Table 3-8: Systemic Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2004-2010
- Figure 3-2 : Systemic Antifungal Drug Market Revenues and Distribution by Product Type, 2004-2010
- Figure 3-3: Systemic Antifungal Drug Market Share of Revenues by Product Type 2004-2011
- Figure 3-4: Systemic Antifungal Drug Market Share by Product Type 2006 and 2011
- Table 3-9: Systemic Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
- Figure 3-5: Systemic Antifungal Drug Market Market Share by Infection Type, 2006
- Table 3-10: Systemic Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
- Figure 3-6: Systemic Antifungal Drug Market Market Share by Geographic Region, 2006
- Table 3-11: Systemic Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
- Figure 3-7: Systemic Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
- Table 3-12: Systemic Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
- Figure 3-8: Systemic Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
- Table 3-13: Systemic Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
- Figure 3-9: Systemic Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006
Chapter Four: Topical Antifungal Drugs
- Table 4-1: Allyamines
- Table 4-2: Topical Azoles
- Table 4-3: Polyene Macrolides
- Table 4-4: Miscellaneous Antifungals
- Table 4-5: New Generic Drug Approvals for Topical Antifungals,
- United States, 2004-2006
- Table 4-6: Topical Antifungal Drugs in Development
- Table 4-7: Topical Antifungal Drug Market, 2004-2011
- Figure 4-8: Topical Antifungal Drug Market, 2004-2011
- Table 4-8: Topical Antifungal Drug Market, 2004-2011
- Figure 4-9: Topical Antifungal Drug Market by Product Type – Revenues, 2004-2011
- Figure 4-10: Topical Antifungal Drug Market by Product Type -Percent Distribution, 2004-2011
- Figure 4-4: Topical Antifungal Drug Market Share by Product Type 2006 and 2011
- Table 4-9: Topical Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
- Figure 4-5: Topical Antifungal Drug Market Market Share by Infection Type, 2006
- Table 4-10 : Topical Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
- Figure 4-6: Topical Antifungal Drug Market Market Share by Geographic Region, 2006
- Table 4-11: Topical Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
- Figure 4-7: Topical Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
- Table 4-12: Topical Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
- Figure 4-8: Topical Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
- Table 4-13: Topical Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
- Figure 4-9: Topical Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006
Chapter Five: Issues and Trends Affecting the
- Antifungal Market
- Table-5-1: New Generic Drug Approvals for Antifungals, United States, 2004-2006
- Table 5-2: Selected Antifungal Rx-to-OTC Switches
Chapter Six: Antifungal Drugs: Total Market
- Size and Forecast
- Table 6-1: The World Market for Antifungal Drugs 2004-2011
- Figure 6-1: The World Market for Antifungal Drugs 2004-2011
- Table 6-2: Topical Antifungal Drug Market by Type (Topical vs Systemic) 2004-2011
- Figure 6-2: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2004-2011
- Figure 6-3: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2006 and 2011
